Citations

Clear

4 citation(s) found for "Colombo, Nicoletta".

Deep Learning for Decision Support in Ovarian Cancer Treatment Planning
Fati, Francesca, Rosanu, Marina , Vitis, Luigi Antonio De , Rota, Alberto , Ribero, Lucia , Colombo, Nicoletta , Peiretti, Michele , Veraldi, Roberto , Spadea, Maria Francesca , Momi, Elena De, Momi, Elena De , Traversa, Alice , Schivardi, Gabriella , Petralia, Giuseppe , Aletti, Giovanni , Angioni, Stefano , Casarin, Jvan , Veraldi, Roberto, Zaffino, Paolo , Multinu, Francesco

Mayo Clinic

No container title available | September 17, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7434368/v1 Get It

Abstract Ovarian cancer is the deadliest gynecologic malignancy worldwide, with a 5-year overall survival rate of approximately 49%. Although complete resection is associated with the most favorable prognosis following primary debulking surgery, accurately assessing tumor resectability at diagnosis remains a major clinical challenge. We propose a decision support system (DSS) designed to predict residual tumor after primary debulking surgery, based on clinical and imaging data available at diagnosis. The system was developed and validated using a retrospective cohort of 465 patients with high-grade serous ovarian cancer, collected at the European Institute of Oncology in Milan, Italy. We developed a deep learning (DL) model that combines pre-trained Vision Transformer encoders with an attention mechanism and a classification head. When evaluated on an independent test cohort of 75 cases, our best-performing model achieved an area under the curve (AUC) of 0.80 (95% CI: 0.68–0.89) and a recall of 0.86 (95% CI: 0.71–0.97), demonstrating discriminatory ability with a particularly low rate of false negatives. Clinically, the model correctly identified 24 out of 28 patients (86%) with non-resectable disease, who would not have benefited from primary debulking surgery. Notably, within this subgroup, the model accurately predicted 93% (13 out of 14) of cases in which surgery was aborted intraoperatively due to unforeseen unresectable disease. These findings suggest that the model could have potential in preventing unnecessary and inappropriate surgical interventions. The proposed DSS is a fully automated, DL–based system for predicting tumor resectability at diagnosis, without the need for manual segmentation or expert evaluation of radiological features and structured clinical parameters. This approach could facilitate and accelerate personalized treatment planning in ovarian cancer. The work is part of the project Under-XAI: understanding ovarian cancer initiation and progression through explainable AI. Project code: PNRR-MAD-2022-12376574.
Letter to the editor—The new FIGO staging system for endometrial cancer: Is the paradigm shift clinically feasible?
Betella, Ilaria , Vitis, Luigi Antonio De , Calidona, Carmelo, Colombo, Nicoletta , De Vitis, Luigi Antonio, Multinu, Francesco

Mayo Clinic

International Journal of Gynecology & Obstetrics | December 7, 2023 | Volume: 164 | Issue: 1 | Pages: 364-365

10.1002/ijgo.15265 | PMID 38055223 Get It

Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Kwan, Tanya T. , Tinker, Anna V. , Oaknin, Ana , Aghajanian, Carol , Lorusso, Domenica , Colombo, Nicoletta , Dean, Andrew , Weberpals, Johanne I. , Severson, Eric A. , Vo, Lan-Thanh, Goble, Sandra, Maloney, Lara , Harding, Thomas , McNeish, Iain A. , Lin, Kevin K. , Swisher, Elizabeth M. , McNeish, Iain A , Swisher, Elizabeth M , Oza, Amit M. , Ray-Coquard, Isabelle L. , Kaufmann, Scott H. , Ledermann, Jonathan A. , Coleman, Robert L.

Mayo Clinic

JAMA Oncology | October 18, 2021 | Volume: 7 | Issue: 12 | Pages: 1772

10.1001/jamaoncol.2021.4664 | PMID 34647981 Get It

TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO‐OVAR OP7).
Mahner, Sven� , Burges, Alexander , Reuß, Alexander , Kraemer, Bernhard , Schmalfeldt, Barbara, Lampe, Bjoern, Fotopoulou, Christina , Lécuru, Fabrice , Querleu, Denis , Greggi, Stefano , Colombo, Nicoletta , Harter, Philipp , Heitz, Florian , Sehouli, Jalid , Schnelzer, Andreas , Wimberger, Pauline , Guyon, Frédéric , Aletti, Giovanni , Bois, Andreas du

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: TPS5602-TPS5602

10.1200/jco.2017.35.15_suppl.tps5602 Get It

TPS5602 Background: Primary cytoreductive surgery (PDS) followed by chemotherapy has been considered as standard management for advanced ovarian cancer patients (pts) over decades. An alternative approach of interval debulking surgery (IDS) following neoadjuvant chemotherapy (NACT) was subsequently reported by two randomized phase III trials (EORTC‐GCG, CHORUS). Owing to important limitations of these studies, especially regarding surgical quality, optimal timing of surgical therapy in advanced ovarian cancer is still unclear. Methods: TRUST is an international open, randomized, controlled multicenter trial investigating overall survival (OS; primary endpoint) after PDS vs NACT and subsequent IDS in pts with FIGO stage IIIB‐IVB ovarian, tubal, and peritoneal carcinoma. Secondary objectives are safety of complete tumor resection, progression‐free survival and quality of life (QoL) as well as surgical morbidity. In order to guarantee adequate surgical quality, participating centers need to fulfill specific quality assurance criteria (e.g. ≥50% complete resection rate in upfront surgery for FIGO IIIB-IV pts, ≥36 debulking-surgeries/year) and agree to independent audits by TRUST Quality committee delegates. A 1:1 randomization to PDS or NACT followed by IDS stratified by center and age‐ECOG combination (ECOG 0 and age ≤65 years vs ECOG > 0 or age > 65 years) is performed. Pts in the PDS arm will undergo surgery followed by 6 cycles of platinum-based chemotherapy, whereas pts in the IDS arm will be treated with 3 cycles of NACT after histologic confirmation of the disease, followed by IDS and subsequently 3 cycles of platinum-based chemotherapy. Intention of surgery for both groups will be complete tumor resection as per guideline recommendations. Health related QoL will be assessed using the EORTC QLQ‐C30, QLQ‐OV28, and EQ‐5D‐3L questionnaires. For sample size planning, we considered a prolongation of median OS from 45 months in the IDS arm to 60 months in the PDS arm (HR 0.75) as clinically relevant. 380 events are needed to obtain a power of 80% in two‐sided log-rank test with significance level of 0.05. The primary analysis will be done in the ITT‐population of 686 randomized pts. By Feb 3 2017, 46 pts were randomized. Clinical trial information: NCT02828618.